Intelligence · Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring ≤24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.
-
US 6262336
Expression of a heterologous protein C in mammary tissue of transgenic animals using a long whey acidic protein promoter
expired -
US 6261567
Overcoming interference in alphavirus immune individuals
expired -
US 6258556
cDNA and genomic clones encoding human .mu. opiate receptor and the purified gene product
expired -
US 6258788
DNA vaccines against tick-borne flaviviruses
expired -
US 6254873
Inactivated dengue virus vaccine
expired -
US 6255105
Nucleotide and deduced amino acid sequences of tumor gene Int6
expired -
US 6245892
Invaplex from gram negative bacteria, method of purification and methods of use
expired -
US 6245560
Vector with multiple target response elements affecting gene expression
expired -
US 6245737
Conjugates of antiviral proteins or peptides and virus or viral envelope glycoproteins
expired -
US 6242482
Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
expired -
US 6241989
Recombinant multivalent viral vaccine
expired -
US 6238677
Starch microcapsules for delivery of active agents
expired -
US 6239116
Immunostimulatory nucleic acid molecules
expired -
US 6238858
Transgenomic viruses
expired -
US 6232336
Nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same
expired -
US 6232086
Method for detecting cancer cells
expired -
US 6228600
Immunoassays for the alpha platelet-derived growth factor receptor
expired -
US 6228987
Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
expired -
US 6229005
DNA sequences of enterically transmitted non-A/non-B hepatitis viral agent
expired -
US 6225088
DNA encoding plasminogen-like growth factor (PLGF) and related embodiments
expired -
US 6224885
Barrier cream comprising hexamethylenetetramine or derivative thereof
expired -
US 6221348
Immune lymphokine-mediated control of Salmonellosis in swine
expired -
US 6217884
Streptococcus pneumoniae 37-kDa surface adhesin a protein
expired -
US 6218596
Enhancement of musculature in non-human mammals expressing c-ski
expired -
US 6217911
sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
expired -
US 6214300
Microencapsulation and electrostatic processing device
expired -
US 6214335
Livestock mucosal competitive exclusion culture to reduce enteropathogenic bacteria
expired -
US 6214347
Multideterminant peptides that elicit helper T-lymphocyte, cytotoxic T lymphocyte and neutralizing antibody responses against HIV-1
expired -
US 6214615
Cloned genes for human dopamine D2 receptors and cell lines expressing same
expired -
US 6214805
RNase L activators and antisense oligonucleotides effective to treat RSV infections
expired -
US 6211168
Methods for preparation and use of 1.alpha.,24 (S)-dihydroxy vitamin D2
expired -
US 6211149
Inhibitors of formation of protease resistant prion protein
expired -
US 6211336
Ataxia-telangiectasia gene
expired -
US 6211230
Method of reducing brain damage resulting from seizures
expired -
US 6210887
Methods for evaluating colon tissue for expression of the DRA (down regulated in adenoma) gene
expired -
US 6211165
Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
expired -
US 6207646
Immunostimulatory nucleic acid molecules
expired -
US 6207157
Conjugate vaccine for nontypeable Haemophilus influenzae
expired -
US 6207416
Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
expired -
US 6204000
Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1
expired -
US 6200558
Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
expired -
US 6197751
Thymosin .alpha.1 promotes tissue repair, angiogenesis and cell migration
expired -
US 6197578
Cells expressing both human CD4 and a human fusion accessory factor associated with HIV infection
expired -
US 6197528
Composition of immunotoxins and retinoids and use thereof
expired -
US 6194547
ETS2 repressor factor (ERF)
expired -
US 6193982
Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
expired -
US 6193949
Method of sire selection using naloxone challenge tests and kits thereof
expired -
US 6194390
Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
expired
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory